Introduction
- LAG3 is an immune checkpoint receptor protein expressed on immune cells, and LAG3 negatively regulates T-cell function and can promote tumor cell immune escape
- Co-blockade of PD1 and LAG3 enhanced anti-tumor responses in preclinical mouse models (ovarian cancer and colon adenocarcinoma)
- Nivolumab (anti-PD1) and Relatlimab (anti-LAG3) combination therapy has been approved to treat metastatic melanoma
- Despite its established prognostic significance in other malignancies, the role of LAG3 as a prognostic or predictive biomarker in urothelial carcinoma (UC) remains inadequately studied